Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00141297
Status:
COMPLETED
Last Update Posted:
2016-01-05
First Post:
2005-08-30
Brief Title:
A Study Of Oral Palbociclib PD-0332991 A Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Phase I Clinical Pharmacokinetic And Pharmacodynamic Evaluation Of 2 Schedules Of Oral PD 0332991 A Cyclin-Dependent Kinase Inhibitor In Patients With Advanced Cancer
Status:
COMPLETED
Status Verified Date:
2015-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
PD-0332991 may work in cancer by stopping cancer cells from multiplying PD-0332991 is in a new class of drugs called cyclin-dependent kinase CDK inhibitors This research study is the first time that PD-0332991 will be given to people PD-0332991 is taken by mouth daily
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None